Blogs

Categories

Select a sub-category to view results

Icon
Films and Coatings
vail 4ml
Pharmaceutical Packaging Components
Icon
Prefillable Systems
Icon
Self Injection Devices
Icon
Vial Containment Solutions
Icon
Washing and Sterilization
Icon
Reconstitution and Transfer Devices

Select a sub-category to view results

Icon
Analytical Lab Services
Icon
Contract Manufacturing
Icon
Fill-Finish
Icon
Regulatory Support

Select a sub-category to view results

Icon
Cell and Gene Therapy Packaging
Icon
Drug Development Process
Icon
Regulatory Challenges
Icon
Transitioning to Combination Products

Select a sub-category to view results

Icon
Corporate Development
Icon
ESG/Sustainability
Icon
One West Team (Employee Culture)
Icon
Our Culture of Giving (Philanthropy)
Icon
Research and Development

Previous Blogs

Analytical Labs

By Lynn Yao

April 03, 2020

With the continuous progress in medical science and technology, drug evaluation criteria in China are also changing and improving. In the past, drug evaluation criteria did not require generic drugs to have the consistent quality and efficacy of innovator drugs; so some had a gap in efficacy. Since 2015, the National Medical Products Administration of China (NMPA), formerly the China Food and Drug Administration (CFDA), rolled out the Generic Quality and Efficacy Consistency Evaluation (GQEC) to improve the quality and efficacy of generic drugs. Generic drugs whose quality and efficacy are deemed equivalent to innovator drugs will enjoy preferential treatment in public hospitals and prescriptions.